Immediate Impact
2 by Nobel laureates 59 standout
Citing Papers
GPCR drug discovery: new agents, targets and indications
2025 Standout
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
2024 Standout
Works of Fernando Moreno being referenced
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
2023
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Fernando Moreno | 261 | 188 | 194 | 64 | 529 | |
| Hamid Mirshahidi | 288 | 209 | 133 | 38 | 593 | |
| Donatella Gambini | 293 | 169 | 143 | 47 | 587 | |
| A. Piga | 301 | 87 | 141 | 36 | 639 | |
| Gang Cai | 177 | 120 | 220 | 43 | 502 | |
| Neyran Kertmen | 321 | 97 | 144 | 54 | 469 | |
| Anne Winther‐Larsen | 174 | 221 | 164 | 39 | 482 | |
| Bartłomiej Tomasik | 136 | 157 | 181 | 69 | 580 | |
| Anna Maria Mosconi | 348 | 88 | 131 | 38 | 538 | |
| Tallal Younis | 326 | 115 | 163 | 34 | 565 | |
| J. Crawford | 267 | 171 | 85 | 43 | 508 |
All Works
Login with ORCID to disown or claim papers
Loading papers...